Castle Biosciences CSTL Dermatologic — NET REVENUES
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's dermatologic — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's dermatologic — NET REVENUES?
- Castle Biosciences (CSTL) reported dermatologic — NET REVENUES of $41.11M in Q1 2026.
- How has Castle Biosciences's dermatologic — NET REVENUES changed year-over-year?
- Castle Biosciences's dermatologic — NET REVENUES decreased by 34.7% year-over-year, from $62.96M to $41.11M.
- What is the long-term trend for Castle Biosciences's dermatologic — NET REVENUES?
- Over 4 years (2021 to 2025), Castle Biosciences's dermatologic — NET REVENUES has grown at a 26.0% compound annual growth rate (CAGR), from $85.75M to $216.37M.
- What does dermatologic — NET REVENUES mean?
- This metric represents the total revenue generated from the sale of genomic diagnostic tests and related services within the company's dermatological cancer product portfolio. It reflects the market adoption and commercial performance of specialized diagnostic tools used by physicians to inform treatment decisions for skin cancers. Tracking this revenue stream provides insight into the company's core business growth and the competitive positioning of its dermatological diagnostic offerings.